Nello Mainolfi - Mar 1, 2022 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Chief Executive Officer, Director
Signature
/s/ Bruce Jacobs, as Attorney-in-Fact
Stock symbol
KYMR
Transactions as of
Mar 1, 2022
Transactions value $
$0
Form type
4
Date filed
3/3/2022, 03:31 PM
Previous filing
Jan 14, 2022
Next filing
May 3, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Award $0 +275K $0.00 275K Mar 1, 2022 Common Stock 275K $38.53 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this stock option shall vest in thirty-six (36) equal monthly installments following March 1, 2022, subject to the reporting person's continued employment through each vesting date.